Group 1 - CervoMed Inc. will host a conference call and webcast on July 28, 2025, to share primary endpoint results from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies [1][2] - The RewinD-LB study is a randomized, 16-week, double-blind, placebo-controlled trial involving 159 patients, with a subsequent 32-week extension phase [4] - The study is primarily funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging [4] Group 2 - Neflamapimod is an investigational oral small molecule that inhibits p38 mitogen-activated protein kinase alpha, aimed at treating synaptic dysfunction in age-related neurologic disorders [5] - The primary outcome measure of the RewinD-LB study is the change in the Clinical Dementia Rating – Sum of Boxes, with secondary endpoints including various cognitive assessments [4] - The study excludes patients with Alzheimer's disease co-pathology, focusing on those with "pure" dementia with Lewy bodies [4]

Core Viewpoint - CervoMed Inc. is set to present new findings from its RewinD-LB Phase 2b study of neflamapimod for dementia with Lewy bodies at the Alzheimer's Association International Congress (AAIC) 2025, highlighting its focus on age-related neurologic disorders [1][3]. Group 1: Presentation Details - CervoMed will deliver both in-person and virtual poster presentations at AAIC 2025, scheduled for July 27 – 31, 2025, in Toronto, Canada [1]. - The in-person poster titled "Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer's disease (AD) Co-Pathology" will be presented on July 27, 2025 [2]. - A virtual presentation titled "Impact of AD Co-Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy Bodies" will also be featured [2]. Group 2: Company Overview - CervoMed is a clinical-stage company dedicated to developing treatments for age-related neurologic disorders, with a focus on neflamapimod, an investigational small molecule that inhibits p38 mitogen-activated protein kinase alpha [3]. - Neflamapimod aims to address synaptic dysfunction, a reversible aspect of neurodegenerative processes in DLB and other neurological disorders, and is currently undergoing evaluation in a Phase 2b study [3].